BIOVIT — Bio Vitos Pharma AB Income Statement
0.000.00%
Last trade - 00:00
- SEK48.15m
- SEK45.07m
- SEK3.00m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.307 | 1.12 | 1.32 | 3 |
Cost of Revenue | |||||
Gross Profit | — | 2.9 | 3.52 | 4.74 | 3 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5.54 | 12 | 15.1 | 16.3 | 15.9 |
Operating Profit | -5.54 | -11.7 | -14 | -14.9 | -12.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.55 | -11.7 | -14 | -14.9 | -12.9 |
Net Income After Taxes | -5.55 | -11.7 | -14 | -14.9 | -12.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.55 | -11.7 | -14 | -14.9 | -12.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.55 | -11.7 | -14 | -14.9 | -12.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.287 | -0.605 | -0.593 | -0.571 | -0.23 |
Dividends per Share |